{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:01:02Z","timestamp":1784833262179,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T00:00:00Z","timestamp":1506297600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11899-017-0400-3","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T03:41:17Z","timestamp":1506310877000},"page":"389-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis"],"prefix":"10.1007","volume":"12","author":[{"given":"Karlyn","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"issue":"1","key":"400_CR1","first-page":"101","volume":"39","author":"B McMahon","year":"2013","unstructured":"McMahon B, Stein BL. Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Semin Thromb Hemost. 2013;39(1):101\u201311.","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"400_CR2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00277-016-2621-2","volume":"95","author":"I Appelmann","year":"2016","unstructured":"\u2022 Appelmann I, Kreher S, Parmentier S, Wolf HH, Bisping G, Kirschner M, et al. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the hemostasis working party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH). Ann Hematol. 2016;95(5):707\u201318. Recommendations by DGHO and GTH for the diagnosis and management of bleeding in MPN.","journal-title":"Ann Hematol"},{"key":"400_CR3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"\u2022 Kaifie A, Kirschner M, Wolf D, Maintz C, H\u00e4nel M, Gattermann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. Journal of hematology & oncology. 2016;9:18. Practice-based data from prospective MPN registry of German Leukemia Alliance to describe the frequency of and risk factors for bleeding and thrombotic complications.","journal-title":"Journal of hematology & oncology"},{"issue":"10","key":"400_CR4","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(10):2224\u201332.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology."},{"issue":"1","key":"400_CR5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33\u201345.","journal-title":"N Engl J Med"},{"issue":"4","key":"400_CR6","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","volume":"115","author":"T Barbui","year":"2010","unstructured":"Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778\u201382.","journal-title":"Blood"},{"issue":"9","key":"400_CR7","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874\u201381.","journal-title":"Leukemia"},{"issue":"2","key":"400_CR8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/bjh.12117","volume":"160","author":"G Bonicelli","year":"2013","unstructured":"Bonicelli G, Abdulkarim K, Mounier M, Johansson P, Rossi C, Jooste V, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol. 2013;160(2):251\u20134.","journal-title":"Br J Haematol"},{"issue":"23","key":"400_CR9","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(23):3179\u201384.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology."},{"issue":"10","key":"400_CR10","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2016.85","volume":"30","author":"V Stefano De","year":"2016","unstructured":"\u2022 De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larr\u00e1n A, Iurlo A, Randi ML, et al. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia. 2016;30(10):2032\u20138. Demonstrated that vitamin K antagonists (VKA) significantly reduce recurrent VTE, with incidence rates of recurrent MPN doubling after stopping VKA.","journal-title":"Leukemia"},{"issue":"19","key":"400_CR11","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"\u2022 Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124(19):3021\u20133. Describes frequency of arterial and venous thrombotic events, risk factors for such, and sites and frequency of recurrent thrombosis in PV as defined by WHO criteria.","journal-title":"Blood"},{"issue":"4","key":"400_CR12","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1160\/TH16-10-0781","volume":"117","author":"W Ageno","year":"2017","unstructured":"Ageno W, Dentali F, Pomero F, Fenoglio L, Squizzato A, Pagani G, et al. Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari syndrome. Thromb Haemost. 2017;117(4):794\u2013800.","journal-title":"Thromb Haemost"},{"issue":"6","key":"400_CR13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bjh.12461","volume":"162","author":"M Sekhar","year":"2013","unstructured":"Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol. 2013;162(6):730\u201347.","journal-title":"Br J Haematol"},{"issue":"2","key":"400_CR14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114\u201324.","journal-title":"N Engl J Med"},{"issue":"22","key":"400_CR15","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857\u20139.","journal-title":"Blood"},{"issue":"26","key":"400_CR16","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128\u201333. quiz 252","journal-title":"Blood"},{"issue":"1","key":"400_CR17","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1002\/ajh.24583","volume":"92","author":"T Barbui","year":"2017","unstructured":"\u2022 Barbui T, Vannucchi AM, Carobbio A, Rumi E, Finazzi G, Gisslinger H, et al. The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. Am J Hematol. 2017;92(1):E5\u20136. Demonstrate arterial hypertension is associated with a significant reduction in thrombosis-free survival in low-risk PV.","journal-title":"Am J Hematol"},{"issue":"2","key":"400_CR18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/MOH.0000000000000312","volume":"24","author":"T Barbui","year":"2017","unstructured":"\u2022 Barbui T, De Stefano V. Management of venous thromboembolism in myeloproliferative neoplasms. Curr Opin Hematol. 2017;24(2):108\u201314. Describes frequency, patterns, and management of primary and recurrent venous thromboembolic events in MPN.","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"400_CR19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2007-07-102665","volume":"111","author":"M Ruggeri","year":"2008","unstructured":"Ruggeri M, Rodeghiero F, Tosetto A, Castaman G, Scognamiglio F, Finazzi G, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood. 2008;111(2):666\u201371.","journal-title":"Blood"},{"issue":"11","key":"400_CR20","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1002\/cncr.21891","volume":"106","author":"N Gangat","year":"2006","unstructured":"Gangat N, Wolanskyj AP, Schwager SM, Mesa RA, Tefferi A. Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia. Cancer. 2006;106(11):2406\u201311.","journal-title":"Cancer"},{"issue":"5","key":"400_CR21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3324\/haematol.13869","volume":"94","author":"V Stefano De","year":"2009","unstructured":"De Stefano V, Za T, Rossi E, Fiorini A, Ciminello A, Luzzi C, et al. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica. 2009;94(5):733\u20137.","journal-title":"Haematologica"},{"issue":"1","key":"400_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.10153","volume":"71","author":"M Ruggeri","year":"2002","unstructured":"Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol. 2002;71(1):1\u20136.","journal-title":"Am J Hematol"},{"issue":"3","key":"400_CR23","first-page":"408","volume":"90","author":"H Gisslinger","year":"2005","unstructured":"Gisslinger H, M\u00fcllner M, Pabinger I, Heis-Vahidi-Fard N, Gisslinger B, Brichta A, et al. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study. Haematologica. 2005;90(3):408\u201310.","journal-title":"Haematologica"},{"issue":"6","key":"400_CR24","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2007","unstructured":"Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109(6):2446\u201352.","journal-title":"Blood"},{"issue":"2","key":"400_CR25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.21593","volume":"85","author":"V Stefano De","year":"2010","unstructured":"De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol. 2010;85(2):97\u2013100.","journal-title":"Am J Hematol"},{"issue":"4","key":"400_CR26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2009-02-206797","volume":"114","author":"T Barbui","year":"2009","unstructured":"Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009;114(4):759\u201363.","journal-title":"Blood"},{"issue":"16","key":"400_CR27","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","volume":"26","author":"A Carobbio","year":"2008","unstructured":"Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(16):2732\u20136.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"7","key":"400_CR28","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","volume":"120","author":"PJ Campbell","year":"2012","unstructured":"Campbell PJ, MacLean C, Beer PA, Buck G, Wheatley K, Kiladjian JJ, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012;120(7):1409\u201311.","journal-title":"Blood"},{"issue":"7","key":"400_CR29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ajh.23217","volume":"87","author":"V Buxhofer-Ausch","year":"2012","unstructured":"Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, M\u00fcllauer L, et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early\/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol. 2012;87(7):669\u201372.","journal-title":"Am J Hematol"},{"issue":"9","key":"400_CR30","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3324\/haematol.12970","volume":"93","author":"PD Ziakas","year":"2008","unstructured":"Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica. 2008;93(9):1412\u20134.","journal-title":"Haematologica"},{"issue":"1","key":"400_CR31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","volume":"33","author":"IJ Dahabreh","year":"2009","unstructured":"Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2009;33(1):67\u201373.","journal-title":"Leuk Res"},{"issue":"3\u20134","key":"400_CR32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2739\/kurumemedj.MS63001","volume":"60","author":"Y Takata","year":"2014","unstructured":"Takata Y, Seki R, Kanajii T, Nohara M, Koteda S, Kawaguchi K, et al. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms. The Kurume medical journal. 2014;60(3\u20134):89\u201397.","journal-title":"The Kurume medical journal"},{"issue":"4","key":"400_CR33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","volume":"124","author":"F Lussana","year":"2009","unstructured":"Lussana F, Caberlon S, Pagani C, Kamphuisen PW, B\u00fcller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res. 2009;124(4):409\u201317.","journal-title":"Thromb Res"},{"issue":"9","key":"400_CR34","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574\u20139.","journal-title":"Leukemia"},{"issue":"9","key":"400_CR35","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","volume":"37","author":"A Carobbio","year":"2009","unstructured":"Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol. 2009;37(9):1016\u201321.","journal-title":"Exp Hematol"},{"issue":"3","key":"400_CR36","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840\u20136.","journal-title":"Blood"},{"issue":"1","key":"400_CR37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620710394474","volume":"2","author":"AM Vannucchi","year":"2011","unstructured":"Vannucchi AM, Pieri L, Guglielmelli P. JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Ther Adv Hematol. 2011;2(1):21\u201332.","journal-title":"Ther Adv Hematol"},{"issue":"10","key":"400_CR38","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"\u2022 Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552\u20135. Describes clinical characteristics associated with CALR mutation in ET, including higher platelet count and lower rate of thrombosis compared to patients with JAK2 and MPL mutations.","journal-title":"Blood"},{"issue":"2","key":"400_CR39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"\u2022 Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111\u201321. Demonstrate that clonal hematopoiesis of indeterminate potential as well as mutations in DNMT3A , TET2 , ASXL1 , and JAK2 are associated with coronary heart disease and myocardial infarctions.","journal-title":"N Engl J Med"},{"key":"400_CR40","doi-asserted-by":"crossref","unstructured":"\u2022 Chu DK, Hillis CM, Leong DP, Anand SS, Siegal DM. Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review. Ann Intern Med. 2017;167(3):170\u2013180. Systematic review of risk\/benefit of aspirin in essential thrombocythemia.","DOI":"10.7326\/M17-0284"},{"issue":"8","key":"400_CR41","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","volume":"116","author":"A Alvarez-Larr\u00e1n","year":"2010","unstructured":"Alvarez-Larr\u00e1n A, Cervantes F, Pereira A, Arellano-Rodrigo E, P\u00e9rez-Andreu V, Hern\u00e1ndez-Boluda JC, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116(8):1205\u201310. quiz 387","journal-title":"Blood"},{"issue":"8","key":"400_CR42","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","volume":"101","author":"A Alvarez-Larr\u00e1n","year":"2016","unstructured":"\u2022 Alvarez-Larr\u00e1n A, Pereira A, Guglielmelli P, Hern\u00e1ndez-Boluda JC, Arellano-Rodrigo E, Ferrer-Mar\u00edn F, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016;101(8):926\u201331. Assessed the risks and benefits of aspirin according to mutation status in patients with low-risk ET and demonstrated that aspirin was associated with a higher incidence of bleeding but had no effect on thrombotic risk for patients with CALR mutation.","journal-title":"Haematologica"},{"issue":"3","key":"400_CR43","first-page":"172","volume":"23","author":"AP Tartaglia","year":"1986","unstructured":"Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol. 1986;23(3):172\u20136.","journal-title":"Semin Hematol"},{"issue":"1","key":"400_CR44","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22\u201333.","journal-title":"N Engl J Med"},{"issue":"3","key":"400_CR45","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","author":"V Stefano De","year":"2008","unstructured":"De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93(3):372\u201380.","journal-title":"Haematologica"},{"issue":"17","key":"400_CR46","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","volume":"332","author":"S Cortelazzo","year":"1995","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132\u20136.","journal-title":"N Engl J Med"},{"issue":"10","key":"400_CR47","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood. 2013;121(10):1720\u20138.","journal-title":"Blood"},{"issue":"5","key":"400_CR48","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426\u201335.","journal-title":"N Engl J Med"},{"issue":"7","key":"400_CR49","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","volume":"101","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016;101(7):821\u20139.","journal-title":"Haematologica"},{"issue":"6","key":"400_CR50","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/MBC.0000000000000446","volume":"27","author":"BT Samuelson","year":"2016","unstructured":"Samuelson BT, Vesely SK, Chai-Adisaksopha C, Scott BL, Crowther M, Garcia D. The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2016;27(6):648\u201352.","journal-title":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis"},{"issue":"6","key":"400_CR51","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00277-015-2330-2","volume":"94","author":"JC Hern\u00e1ndez-Boluda","year":"2015","unstructured":"\u2022 Hern\u00e1ndez-Boluda JC, Arellano-Rodrigo E, Cervantes F, Alvarez-Larr\u00e1n A, G\u00f3mez M, Barba P, et al. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol. 2015;94(6):911\u20138. Demonstrated that vitamin K antagonists reduce recurrent thrombotic events in PV and ET without a significant increase in the rate of major bleeding.","journal-title":"Ann Hematol"},{"issue":"2","key":"400_CR52","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajh.23895","volume":"90","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90(2):162\u201373.","journal-title":"Am J Hematol"},{"issue":"6","key":"400_CR53","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761\u201370.","journal-title":"J Clin Oncol"},{"issue":"6","key":"400_CR54","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.blre.2010.08.002","volume":"24","author":"E Papadakis","year":"2010","unstructured":"Papadakis E, Hoffman R, Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev. 2010;24(6):227\u201332.","journal-title":"Blood Rev"},{"issue":"4","key":"400_CR55","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","volume":"26","author":"G Finazzi","year":"2012","unstructured":"Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26(4):716\u20139.","journal-title":"Leukemia"},{"issue":"4","key":"400_CR56","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ajh.2830200408","volume":"20","author":"DH Buss","year":"1985","unstructured":"Buss DH, Stuart JJ, Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol. 1985;20(4):365\u201372.","journal-title":"Am J Hematol"},{"issue":"8","key":"400_CR57","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/leu.2013.99","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Barbui T. Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. Leukemia. 2013;27(8):1617\u201320.","journal-title":"Leukemia"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-017-0400-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0400-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0400-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T06:23:59Z","timestamp":1719469439000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-017-0400-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,25]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["400"],"URL":"https:\/\/doi.org\/10.1007\/s11899-017-0400-3","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,25]]}}}